Beyond Innovation: What It Takes to Build Successful MedTech Companies in France

Megha Roy
Written by Megha Roy

France has many of the ingredients needed to build successful medical technology companies: scientific and academic excellence, university hospitals engaged in research and clinical practice, strong engineering capabilities and public funding mechanisms that support early-stage innovation. Yet, for Julie Rachline, President of LallianSe a Catalyst in Life Sciences, the challenge is no longer simply producing innovation. It is connecting these strengths to create companies that can bring technologies to market, attract investment and expand internationally.

“The strength of an ecosystem is not only the quality of its individual players, but their ability to work together around the same trajectory,” she says.

Speaking to MedTech World, Julie discusses the opportunities and challenges facing French MedTech, from the transition from laboratory research to commercial adoption to the financing requirements for international growth. Drawing on around a decade of experience as a healthcare investor and her experience as co-founder of BrainTale – a spin-off of the Paris Region Greater hospitals (AP-HP) and for which she has been designated as Female Leader of the Year at Medtech Malta 2024 -she argues that successful companies must plan for clinical evidence, regulation, reimbursement, financing and market access as interconnected parts of their business strategy.

Bridging the gap between research and the market

France’s scientific capabilities provide a strong foundation for medical technology innovation. However, converting promising research into commercially viable products remains a complex process.

Julie identifies a disconnect between the different stakeholders involved in bringing a medical technology to market. Researchers seek proof of concept, clinicians look for evidence of patient benefit, regulators assess safety and performance, investors evaluate value creation, and hospital buyers need a viable purchasing proposition.

Each perspective is legitimate, but when these requirements are not aligned, promising projects can stall between prototype development and the first purchase order.

Julie experienced this challenge firsthand as co-founder of BrainTale, a company that measures the brain through white matter assessment and a spin-off of Assistance Publique–Hôpitaux de Paris (AP-HP), the Paris region’s public hospital network. Despite having functional technology and clinical interest, the company struggled to establish a clear route to market access in Europe and did not survive in its original form.

The experience reinforced a central lesson: scientific merit alone does not guarantee commercial success. Companies must establish early how their technology will be adopted, who will pay for it and what evidence will support purchasing decisions.

Funding innovation beyond the early stages

France has a well-developed system of public support for early-stage innovation. Organisations such as Bpifrance, alongside France 2030 programmes, regional schemes, innovation grants and loans, and the research tax credit, help companies develop technologies and reduce early-stage risk.

The challenge becomes more pronounced when companies approach expensive milestones, including the generation of clinical evidence, regulatory approvals, industrialisation, commercial expansion, and international market entry.

According to France Biotech’s Panorama France HealthTech 2026, 41% of French HealthTech companies report cash-flow tensions, while closing a funding round takes an average of ten months. Snitem estimates that French medical device start-ups raised approximately €428 million in 2025.

These pressures make it essential for founders to understand what investors are financing. Public funding can be extremely structuring, but it cannot replace a sufficiently robust equity story capable of attracting the right private capital.

“Investors do not finance a technology, they finance an equity story that includes how the technology will be monetized,” Julie explains.

That story must connect clinical evidence and regulatory planning with market demand, purchasing decisions, revenue generation and a potential exit. Financing should follow milestones that meaningfully increase company value, rather than simply fund another period of activity.

Market access must start on day one

Clinical evidence, regulatory strategy and reimbursement are often addressed separately, sometimes by different teams at different stages of development. Julie believes this approach can lead to costly misalignment.

Instead, founders should consider these elements together from the company’s creation. The central questions are straightforward: what is being sold, who is the intended customer, who pays, and what evidence is required to support adoption?

A clinical study may produce excellent scientific results but still fail to meet the requirements of a payer or purchasing hospital. Similarly, a product may satisfy regulatory requirements without having a viable reimbursement pathway or a clear route to procurement.

France and other European markets offer mechanisms designed to support innovation, including the forfait innovation and early access pathways for certain software medical devices. However, these do not cover every product or commercial situation. For Julie, market access must therefore be built into a realistic business plan that considers the entire journey from development to deployment. As Fabienne Bartoli of France’s General Inspectorate of Social Affairs put it during a discussion with CEOs this summer, “ an innovation only truly becomes an innovation once it reaches the market”.

International expansion requires preparation

For French MedTech companies, international expansion increasingly forms part of the strategy from the outset. The United States is a particularly important destination because of its market size, access to capital and role in potential company exits. According to France Biotech’s latest Panorama, nearly three-quarters of French HealthTech companies already on the market target international markets, highlighting how international expansion has become an integral part of the sector’s development strategy1.

However, Julie cautions against treating internationalisation as an opportunity to pursue without a clearly defined objective. Companies must establish whether they are expanding to attract investment, access clinical or regulatory pathways, pursue reimbursement, secure partnerships or position themselves for acquisition. Each objective requires a different sequence of decisions, capabilities and relationships.

Preparation is especially important when entering the US market. Companies should anticipate their Food and Drug Administration (FDA) strategy early enough to ensure that evidence generated in Europe can support their intended regulatory pathway. They must also understand that American clinicians, payers and buyers may have different expectations from their European counterparts.

Building a local presence takes time, money and credibility. Entering too early with a product and evidence package designed exclusively for Europe can create difficulties, while waiting too long may leave a company without sufficient capital to establish itself properly.

Julie emphasises the importance of local expertise, operational readiness and appropriate governance. Technology cannot replace a compelling commercial proposition that local investors, customers and partners can readily understand.


What international companies should know about France

The same principles apply to international businesses considering France as a base for clinical research, manufacturing or European operations.

France offers established academic and clinical partners, recognised research capabilities, engineering talent and public support mechanisms that can reduce early development costs. However, international companies must also navigate hospital decision-making cycles, national and regional structures, reimbursement rules, public procurement and relationships within a relatively concentrated ecosystem.

Julie advises companies to view local expertise as an investment rather than an overhead. Working with partners who understand the system can help identify the right stakeholders, establish relationships and navigate the practical requirements of operating in France.

The opportunity lies in combining the country’s scientific strengths with an informed understanding of how its healthcare and commercial systems work.

Building companies around a clear trajectory

Beyond technology, Julie sees several common characteristics among successful MedTech companies. They have a clear vision of the problem they are solving, their target market and the type of business they intend to build. They bring in the right expertise at the appropriate stages, rather than hiring ahead of their needs, and organise development around milestones that create value and can be financed.

They also anticipate what comes next: the requirements of future funding rounds, upcoming regulatory milestones, the expectations of buyers and the interests of potential acquirers. Scenario planning, budget management and effective governance are integral to this process.

These considerations will also inform Julie’s participation at MedTech World Europe in Malta this November. On 13 November, she will bring together CEOs and investors for a workshop on successful exit strategies, encouraging companies to consider value creation and shareholder outcomes well before an exit becomes imminent.

Her message to the wider European MedTech community is clear. France and Europe have the scientific capabilities, talent and international ambition to develop globally relevant companies. The next challenge is ensuring these strengths translate into commercial success.

That requires founders, investors, clinicians, regulators and industry partners to work towards a shared trajectory, with market access, financing and international growth considered from the beginning. This is precisely the kind of dialogue that LallianSe aims to foster: bringing together the right people, expertise and perspectives to help healthcare innovations become sustainable companies and reach the patients who need them.

1France Biotech, Panorama France HealthTech 2026 (published February 2026, 2025 data).